headache with tirzepatide Unanticipated Adverse Events Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring 18 Possible Side Effects of

GLP-1 medicines have changed what is possible in obesity and type 2 diabetes, but they require chronic, high-dose systemic exposure that many patients cannot or do not sustain, said Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health

And as a super bonus, there are also actives that durably consolidate the skin barrier (oats, ceramides, ginger)

ACT 1: Beyond GLP-1 Why Triple Agonists Are Rewriting the Weight Loss Ceiling To understand why newer drugs like Retatrutide are generating so much excitement in obesity medicine, you first need to understand what current medications actually do and where their limitations lie

Phase II data showed 15.6% weight loss at week 32

Wegovy is a GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or those who are overweight with weight-related conditions

Multiple GI conditions have been linked to a higher abundance of hydrogen sulfide in the digestive tract